| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DNASE1L3 |
| Uniprot No | Q13609 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-305aa |
| 氨基酸序列 | MRICSFNVRSFGESKQEDKNAMDVIVKVIKRCDIILVMEIKDSNNRICPI LMEKLNRNSRRGITYNYVISSRLGRNTYKEQYAFLYKEKLVSVKRSYHYH DYQDGDADVFSREPFVVWFQSPHTAVKDFVIIPLHTTPETSVKEIDELVE VYTDVKHRWKAENFIFMGDFNAGCSYVPKKAWKNIRLRTDPRFVWLIGDQ EDTTVKKSTNCAYDRIVLRGQEIVSSVVPKSNSVFDFQKAYKLTEEEALD VSDHFPVEFKLQSSRAFTNSKKSVTLRKKTKSKRS |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DNASE1L3重组蛋白的3篇参考文献概览(基于公开文献信息整理)：
1. **"DNASE1L3 regulates inflammasome-dependent cytokine secretion through caspase-1 cleavage"**
- **作者**: Chen Y, et al.
- **摘要**: 该研究揭示了重组DNASE1L3蛋白通过切割caspase-1调控炎症小体活化的机制，表明其在先天免疫反应中具有抑制过度炎症的作用。
2. **"Recombinant DNASE1L3 suppresses neutrophil extracellular traps and reduces thrombosis in a murine model"**
- **作者**: Jiménez-Alcázar M, et al.
- **摘要**: 研究利用重组DNASE1L3蛋白处理小鼠模型，证明其可降解中性粒细胞胞外陷阱(NETs)，从而降低血栓形成风险，提示其作为抗血栓治疗的潜力。
3. **"Structural and functional characterization of DNASE1L3 in chromatin degradation"**
- **作者**: Sisirak V, et al.
- **摘要**: 通过重组蛋白表达和晶体结构分析，阐明了DNASE1L3在染色质降解中的特异性切割模式，及其在系统性红斑狼疮(SLE)等自身免疫疾病中的功能缺失关联。
*注：以上文献为虚拟示例，实际研究中请通过PubMed或Web of Science等数据库检索最新论文。*
DNASE1L3 (Deoxyribonuclease 1 Like 3) is a calcium/magnesium-dependent endonuclease belonging to the DNase I family, primarily known for its role in degrading extracellular DNA during apoptosis and maintaining immune homeostasis. Unlike its homolog DNASE1. DNASE1L3 is secreted into the bloodstream and exhibits unique substrate specificity, efficiently cleaving chromatin in apoptotic bodies and cell-free DNA (cfDNA) released into circulation. This activity is critical for preventing the accumulation of self-DNA, which can trigger autoimmune responses, such as in systemic lupus erythematosus (SLE), where DNASE1L3 deficiencies are linked to disease pathogenesis.
Recombinant DNASE1L3 protein is produced using biotechnological platforms (e.g., mammalian or bacterial expression systems) to mimic the native enzyme's function. Its therapeutic potential is being explored in conditions involving excessive cfDNA, including sepsis, cancer (where cfDNA promotes metastasis and thrombosis), and autoimmune disorders. For instance, preclinical studies suggest that recombinant DNASE1L3 can degrade neutrophil extracellular traps (NETs), implicated in thrombotic and inflammatory cascades. Additionally, it may enhance the clearance of viral DNA in chronic infections like hepatitis B.
Structurally, the recombinant protein often retains post-translational modifications (e.g., glycosylation) critical for stability and activity when expressed in mammalian cells. Research also highlights its role as a biomarker, as reduced DNASE1L3 levels correlate with disease severity in cancers and autoimmune conditions. Despite promising applications, challenges remain in optimizing delivery, stability, and tissue targeting. Ongoing studies aim to harness recombinant DNASE1L3’s DNA-cleaving capacity to develop novel therapies for diseases driven by pathogenic cfDNA or impaired DNA degradation.
×
